- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03783585
Feasibility of Web-based CBT-I Intervention in Individuals With Multiple Sclerosis
August 26, 2019 updated by: Catherine Siengsukon, PT, PhD, University of Kansas Medical Center
Assessment of the Feasibility of a Web-based CBT-I Intervention to Improve Sleep Quality and Fatigue in Individuals With Multiple Sclerosis
Forty individuals with multiple sclerosis (MS) will be randomly assigned to a 6-week web-based cognitive behavior therapy for insomnia intervention (wCBT-I) or to wCBT-I plus biweekly support meetings with research personnel via phone or video.
Questionnaires will be used to assess sleep quality, fatigue, and satisfaction.
Recruitment, retention, attrition, adherence, and safety information will also be collected.
This study is significant because addressing insomnia symptoms through CBT-I could be a low-cost, low-risk, non-pharmacological options for improving sleep quality and MS symptoms in individuals with MS.
This study is innovative because CBT-I has never been delivered via a web-based application to individuals with MS which may increase access to services.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
44
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Catherine Siengsukon
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18-80 years old
- diagnosis of MS by physician
- report of difficulty falling asleep, maintaining sleep, or waking up too early at least 3 nights/week for the past 6 months
- ≥10 on Insomnia Severity Index (ISI)
- English speaking
- reports access to internet service and phone
- has a high school diploma to serve as a proxy measurement of reading ability to ensure adequate reading ability to participate in the study.
Exclusion Criteria:
- known untreated sleep disorder (such as sleep apnea or restless leg syndrome)
- >3 on STOP BANG indicating risk of sleep apnea
- increased risk of restless leg syndrome
- nervous system disorder other than MS
- relapse and/or corticosteroid use in past 8 weeks
- score of ≥15 on the Patient Health Questionnaire (PHQ-9) indicating severe depression or endorse any suicidal ideation (answer 1, 2 or 3 on #9 of the PHQ-9)
- performs shift-work.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: cognitive behavioral therapy for insomnia (CBT-I)
Participants randomized to this arm will participate in a 6-week web-based cognitive behavioral therapy for insomnia (CBT-I) program.
|
The web-based CBT-I program is a 6-week interactive, online program that delivers typical CBT-I treatment techniques of stimulus control, sleep restriction, behavioral modifications, and cognitive restructuring.
|
Experimental: CBT-I + biweekly support
Participants randomized to this arm will participate in a 6-week web-based CBT-I program.
In addition, biweekly support consisting of one-on-one, semi-structured, online video-chat sessions (via HIPAA-compliant Zoom) or phone calls will be conducted every other week.
|
The web-based CBT-I program is a 6-week interactive, online program that delivers typical CBT-I treatment techniques of stimulus control, sleep restriction, behavioral modifications, and cognitive restructuring.
Individuals randomized into the CBT-I + biweekly support will participate in CBT-I as described as well as a biweekly phone call or video call with research personnel for motivational interviewing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in Insomnia Severity Index (ISI)
Time Frame: baseline and week 8
|
The ISI is a valid and reliable measure of sleep difficulties and consists of 7 questions each rated on a 0-4 scale.
The range of scores on the ISI is 0-28, with ≥10 suggesting clinical insomnia
|
baseline and week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in Pittsburgh Sleep Quality Index (PSQI)
Time Frame: baseline and week 8
|
The PSQI is a well-validated and reliable measure of sleep quality and consists of 9 items within 7 sleep categories.
The 7 sleep category scores are summed to form a single global score ranging from 0-21.
A global score of >5 reflects poor sleep quality
|
baseline and week 8
|
change in Modified Fatigue Impact Scale (MFIS)
Time Frame: baseline and week 8
|
The MFIS consists of 21 items with 3 subscales: physical, cognitive, and psychosocial.
The score on the 21 items are scored with a range of 0-84 with a higher score indicating a greater impact of fatigue.
|
baseline and week 8
|
change in Fatigue Severity Scale (FSS)
Time Frame: baseline and week 8
|
Fatigue Severity Scale (FSS) assesses the impact of fatigue on activities for the week prior and consists of 9 questions.
The mean of the 9 scores is calculated with a range of 0-7.
|
baseline and week 8
|
change in Multiple Sclerosis Impact Scale (MSIS)
Time Frame: baseline and week 8
|
MSIS-29 is total of 29 items scale, with subscales of physical (20 items) and psychological (9 items).
Responses computed in a range from 0-100, and higher scores indicating a worse quality of life due to physical and physiological impacts of MS.
|
baseline and week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2018
Primary Completion (Actual)
August 20, 2019
Study Completion (Actual)
August 20, 2019
Study Registration Dates
First Submitted
October 1, 2018
First Submitted That Met QC Criteria
December 18, 2018
First Posted (Actual)
December 21, 2018
Study Record Updates
Last Update Posted (Actual)
August 28, 2019
Last Update Submitted That Met QC Criteria
August 26, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00142464
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Cognitive behavioral therapy for insomnia
-
University of ArizonaRecruitingSleep Initiation and Maintenance DisordersUnited States
-
Stanford UniversityNational Institute of Nursing Research (NINR)Completed
-
Dartmouth-Hitchcock Medical CenterCrohn's and Colitis FoundationCompletedPain | Inflammation | Insomnia | Sleep Disturbance | Crohn DiseaseUnited States
-
Balearic Islands Health Service (Ibsalut)Completed
-
Southeast Louisiana Veterans Health Care SystemVISN 16 Mental Illness Research, Education and Clinical Center (MIRECC)CompletedSleep Initiation and Maintenance DisordersUnited States
-
University of RochesterNational Institute on Aging (NIA)CompletedInsomnia | Knee Pain | Osteoarthritis of the KneeUnited States
-
University of RochesterNational Institute of Nursing Research (NINR)CompletedDepression | Sleep | Stress Disorders, Post-TraumaticUnited States
-
University of California, DavisRecruiting
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingGambling Disorder TreatmentFrance
-
University of PennsylvaniaChildren's Hospital of PhiladelphiaRecruitingCaregiver Burden | Autism Spectrum Disorder | Insomnia ChronicUnited States